Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/16/2019
Start Date:January 15, 2014

Use our guide to learn which trials are right for you!

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation

This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab
with estrogen deprivation to see how they work compared to docetaxel, carboplatin,
trastuzumab, and pertuzumab without estrogen deprivation in treating patients with hormone
receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer
that is operable or has spread from where it started to nearby tissue or lymph nodes (locally
advanced). Drugs used in chemotherapy, such as docetaxel, carboplatin, trastuzumab, and
pertuzumab, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving more than
one drug (combination chemotherapy) may kill more tumor cells. Estrogen can cause the growth
of breast cancer cells. Hormone therapy using goserelin acetate and aromatase inhibition
therapy may fight breast cancer by blocking the use of estrogen by the tumor cells. Radiation
therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy and
radiation therapy with or without hormone therapy may be an effective treatment for hormone
receptor-positive, HER2-positive, operable or locally advanced breast cancer.

PRIMARY OBJECTIVES:

I. To determine whether the addition of estrogen deprivation to neoadjuvant therapy
consisting of therapy of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) yields a
greater rate of pathologic complete response (pCR) (breast and nodes) than TCHP alone when
administered to women with operable, hormone receptor-positive, HER2-positive breast cancer.

SECONDARY OBJECTIVES:

I. To determine whether the addition of estrogen deprivation to neoadjuvant therapy
consisting of TCHP will increase the pCR rate in the breast compared to TCHP alone when
administered to women with operable, hormone receptor-positive, HER2-positive breast cancer.

II. To determine whether the addition of estrogen deprivation to neoadjuvant therapy
consisting of TCHP improves recurrence-free interval (RFI) in women with operable, hormone
receptor-positive, HER2-positive breast cancer.

III. To determine whether the addition of estrogen deprivation to neoadjuvant therapy
consisting of TCHP improves overall survival (OS) in women with operable, hormone
receptor-positive, HER2-positive breast cancer.

IV. To compare the rates of second primary invasive cancer by treatment arm. V. Assessment of
patterns of pCR, RFI, and OS by menopausal status. VI. To evaluate the cardiac toxicity
associated with each of the regimens. VII. To compare the effect of adding estrogen
deprivation to neoadjuvant therapy on endocrine-related symptoms in all patients by treatment
arm.

VIII. To compare the effect of adding estrogen deprivation to neoadjuvant therapy on
vasomotor symptoms, musculoskeletal, and vaginal complaints as well as quality of life.

IX. To determine a relationship between pCR and a potential mechanism of
resistance/sensitivity in hormone receptor-positive, HER2-positive tumors.

X. To evaluate tumor infiltrating lymphocytes (TILs) and immune biomarkers as predictors of
pCR.

XI. To study early changes in TILs and other immune biomarkers in response to TCHP.

OUTLINE: Patients are randomized to 1 of 2 treatments arms.

NEOADJUVANT:

ARM I: Patients receive docetaxel intravenously (IV) over 60 minutes, carboplatin IV over
30-60 minutes, trastuzumab IV over 30-90 minutes, and pertuzumab IV over 30-60 on day 1.
Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or
unacceptable toxicity. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to
course 3 of treatment.

ARM II: All patients receive docetaxel, carboplatin, trastuzumab, and pertuzumab as in arm I.
Premenopausal patients also receive goserelin acetate subcutaneously (SC) every 28 days until
surgery and aromatase inhibition therapy at the investigator's discretion daily until 1 day
before surgery. Postmenopausal patients receive aromatase inhibition therapy at the
investigator's discretion daily until 1 day before surgery. Patients enrolled after Amendment
#4 undergo 2 core biopsies prior to course 3 of treatment.

SURGERY: Patients undergo lumpectomy or mastectomy.

RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.

ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year.

After completion of study treatment, patients are followed up every 6, 9, 12, and 18 months
for 5 years.

Inclusion Criteria:

- Patients should have a life expectancy of at least 10 years, excluding their diagnosis
of breast cancer; (comorbid conditions should be taken into consideration, but not the
diagnosis of breast cancer)

- Women of reproductive potential must agree to use an effective non-hormonal method of
contraception during study therapy (chemotherapy, trastuzumab, pertuzumab, and
estrogen deprivation therapy) and for at least 7 months after the last dose of study
therapy

- Submission of tumor samples is required for all patients; the local pathology
department policy regarding release of tumor samples must be considered in the
screening process; patients whose tumor samples are located in a pathology department
that by policy will not submit any samples for research purposes should not be
approached for participation in the B-52 trial

- The patient must have signed and dated an Institutional Review Board (IRB)-approved
consent form that conforms to federal and institutional guidelines

- The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
of 0 or 1

- Clinical staging for the primary tumor can be cT1c (must be 2.0 cm) or T2-T4 if
clinically node negative; if the regional lymph nodes are cN1 and cytologically or
histologically positive or if cN2-N3 with or without a biopsy, the primary breast
tumor can be cT0-T4

- The diagnosis of invasive adenocarcinoma of the breast must have been made by core
needle biopsy

- Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound,
and/or magnetic resonance imaging [MRI]) within 6 weeks prior to randomization; if
suspicious or abnormal, fine needle aspirate (FNA) or core biopsy is recommended, also
within 6 weeks prior to randomization; findings of these evaluations will be used to
determine the nodal status prior to randomization:

- Nodal status - negative

- Imaging of the axilla is negative

- Imaging is suspicious or abnormal but the FNA or core biopsy of the
questionable node(s) on imaging is negative

- Nodal status - positive

- FNA or core biopsy of the node(s) is cytologically or histologically
suspicious or positive

- Imaging is suspicious or abnormal but FNA or core biopsy was not performed

- Patients may be premenopausal or postmenopausal at the time of randomization; for
study purposes, postmenopausal is defined as:

- Age 56 or older with no spontaneous menses for at least 12 months prior to study
entry; or

- Age 55 or younger with no spontaneous menses for at least 12 months prior to
study entry (e.g., spontaneous or secondary to hysterectomy) and with a
documented estradiol level in the postmenopausal range according to local
institutional/laboratory standard; or

- Documented bilateral oophorectomy

- The tumor must have been determined to be HER2-postive as follows:

- Immunohistochemistry (IHC) 3+ or

- In situ hybridization (ISH)-positive (defined by ratio of HER2 to circulating
endothelial progenitors [CEP]17 >= 2.0 or HER2 gene copy number >= 6 per nucleus)

- The tumor must have been determined to be estrogen receptor (ER) and/or progesterone
(PgR) positive assessed by current American Society of Clinical Oncology
(ASCO)/College of American Pathologist (CAP) guideline recommendations for hormone
receptor testing; patients with >= 1% ER or PgR staining by IHC are considered
positive

- Absolute neutrophil count (ANC) must be >= 1200/mm^3

- Platelet count must be >= 100,000/mm^3

- Hemoglobin must be >= 10 g/dL

- Total bilirubin must be =< upper limit of normal (ULN) for the lab unless the patient
has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar
syndrome involving slow conjugation of bilirubin

- Alkaline phosphatase must be =< 2.5 x ULN for the lab

- Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab

- Alkaline phosphatase and AST may not both be > the ULN; for example, if the alkaline
phosphatase is > the ULN but =< 2.5 x ULN, the AST must be =< the ULN; if the AST is >
the ULN but =< 1.5 x ULN, the alkaline phosphatase must be =< ULN; Note: If alanine
aminotransferase (ALT) is performed instead of AST (per institution's standard
practice), the ALT value must be =< 1.5 x ULN; if both were performed, the AST must be
=< 1.5 x ULN

- Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the
study if liver imaging (computed tomography [CT], MRI, positron emission tomography
[PET]-CT, or PET scan) performed within 6 weeks prior to randomization does not
demonstrate metastatic disease and the requirements are met

- Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone
pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan
performed within 6 weeks prior to randomization does not demonstrate metastatic
disease

- Within 6 weeks prior to randomization, the most recent serum creatinine must be =< ULN
or measured or calculated creatinine clearance must be > 60 mL/min

- Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days
prior to randomization; (LVEF assessment performed by 2-dimensional [2-D]
echocardiogram is preferred; however, multi gated acquisition scan [MUGA] scan may be
substituted based on institutional preferences); the LVEF must be >= 50% regardless of
the cardiac imaging facility's lower limit of normal; note: since the pre-entry LVEF
serves as the baseline for comparing subsequent LVEF assessments, it is critical that
this baseline study be an accurate assessment; if the baseline LVEF is > 65%, the
investigator is encouraged to have the accuracy of the initial LVEF result confirmed
and repeat the test if the accuracy is uncertain

Exclusion Criteria:

- FNA alone to diagnose the breast cancer

- Excisional biopsy or lumpectomy performed prior to randomization

- Surgical axillary staging procedure prior to randomization; pre-neoadjuvant therapy
sentinel node biopsy is not permitted

- Definitive clinical or radiologic evidence of metastatic disease; (chest imaging
[mandatory for all patients] and other imaging [if required] must have been performed
within 90 days prior to randomization)

- Synchronous bilateral invasive breast cancer

- Synchronous or previous contralateral invasive breast cancer; (patients with
synchronous and/or previous contralateral ductal carcinoma in situ [DCIS] or lobular
carcinoma in situ [LCIS] are eligible)

- Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS;
(patients with synchronous or previous ipsilateral LCIS are eligible)

- Treatment including radiation therapy (RT), chemotherapy, targeted therapy, or
endocrine therapy for the currently diagnosed breast cancer prior to randomization

- Previous endocrine therapy such as raloxifene or tamoxifen (or other selective
estrogen receptor modulator [SERM]) or an aromatase inhibitor for any malignancy

- Previous therapy with anthracycline, taxanes, carboplatin, trastuzumab, or other HER2
targeted therapies for any malignancy

- Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement
therapy, etc. (these patients are eligible if this therapy is discontinued prior to
randomization)

- History of non-breast malignancies (except for in situ cancers treated only by local
excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior
to randomization

- Cardiac disease (history of and/or active disease) that would preclude the use of the
drugs included in the treatment regimens; this includes but is not confined to:

- Active cardiac disease:

- Angina pectoris that requires the use of anti-anginal medication;

- Ventricular arrhythmias except for benign premature ventricular
contractions;

- Supraventricular and nodal arrhythmias requiring a pacemaker or not
controlled with medication;

- Conduction abnormality requiring a pacemaker;

- Valvular disease with documented compromise in cardiac function; and

- Symptomatic pericarditis

- History of cardiac disease:

- Myocardial infarction documented by elevated cardiac enzymes or persistent
regional wall abnormalities on assessment of left ventricular (LV) function;

- History of documented congestive heart failure (CHF); and

- Documented cardiomyopathy

- Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg
or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if
initiation or adjustment of BP medication lowers pressure to meet entry criteria)

- Active hepatitis B or hepatitis C with abnormal liver function tests

- Intrinsic lung disease resulting in dyspnea

- Poorly controlled diabetes mellitus

- Active infection or chronic infection requiring chronic suppressive antibiotics

- Patients known to be human immunodeficiency virus (HIV) positive with a baseline
cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of
acquired immune deficiency syndrome (AIDS) indicator conditions; patients taking
anti-retroviral therapy that may have a potential overlapping toxicity with the study
therapy are not eligible

- Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral
sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events
version 4.0 (CTCAE v4.0)

- Malabsorption syndrome, ulcerative colitis, resection of the stomach or small bowel,
or other disease significantly affecting gastrointestinal function

- Other non-malignant systemic disease that would preclude treatment with any of the
treatment regimens or would prevent required follow-up

- Conditions that would prohibit administration of corticosteroids

- Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day
methylprednisolone equivalent (excluding inhaled steroids)

- Known hypersensitivity to any of the study drugs or any of the ingredients or
excipients of these drugs (e.g., polysorbate 80), including sensitivity to benzyl
alcohol

- Pregnancy or lactation at the time of study entry; (note: pregnancy testing must be
performed within 2 weeks prior to randomization according to institutional standards
for women of childbearing potential)

- Psychiatric or addictive disorders or other conditions that, in the opinion of the
investigator, would preclude the patient from meeting the study requirements

- Use of any investigational product within 30 days prior to randomization
We found this trial at
740
sites
1100 West Stewart Drive
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Bremerton, Washington 98310
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
802-656-8990
?
mi
from
Burlington, VT
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
'Aiea, Hawaii 96701
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Abilene, Texas 79601
?
mi
from
Abilene, TX
Click here to add this to my saved trials
Adrian, Michigan 49221
?
mi
from
Adrian, MI
Click here to add this to my saved trials
818 Riverside Ave.
Adrian, Michigan 49221
(517) 265-0900
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
?
mi
from
Adrian, MI
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaconda, Montana 59711
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anaheim, California 92806
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Antioch, CA
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
364 White Oak St
Asheboro, North Carolina 27203
(336) 625-5151
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
?
mi
from
Asheboro, NC
Click here to add this to my saved trials
Asheville, North Carolina 28803
?
mi
from
Asheville, NC
Click here to add this to my saved trials
?
mi
from
Athens, GA
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Auburn, California 95602
?
mi
from
Auburn, CA
Click here to add this to my saved trials
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, Washington 98001
?
mi
from
Auburn, WA
Click here to add this to my saved trials
Augusta, Georgia 30912
?
mi
from
Augusta, GA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
(303) 695-2600
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
?
mi
from
Bainbridge Island, WA
Click here to add this to my saved trials
Baldwin Park, California 91706
?
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
?
mi
from
Ballwin, MO
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
155 5th St NE
Barberton, Ohio 44203
(330) 615-3000
Summa Barberton Hospital Summa Barberton Hospital is a full member of Summa Health System and...
?
mi
from
Barberton, OH
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
?
mi
from
Beaver, PA
Click here to add this to my saved trials
Bellevue, Washington 98004
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Bellflower, California 90706
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
Bemidji, Minnesota 56601
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
?
mi
from
Berlin, VT
Click here to add this to my saved trials
Billings, Montana 59101
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59101
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Bloomington, Illinois 61701
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boone, Iowa 50036
?
mi
from
Boone, IA
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
?
mi
from
Boulder, CO
Click here to add this to my saved trials
960 W Wooster St
Bowling Green, Ohio 43402
419-353-5419
Toledo Clinic Cancer Centers-Bowling Green Our doctors evaluate and make recommendations regarding cancer treatment for...
?
mi
from
Bowling Green, OH
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
?
mi
from
Brainerd, MN
Click here to add this to my saved trials
Branson, Missouri 65616
?
mi
from
Branson, MO
Click here to add this to my saved trials
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
?
mi
from
Brewer, ME
Click here to add this to my saved trials
Bridgeport, West Virginia 26330
?
mi
from
Bridgeport, WV
Click here to add this to my saved trials
Burien, Washington 98166
?
mi
from
Burien, WA
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
?
mi
from
Burlingame, CA
Click here to add this to my saved trials
Burlington, North Carolina 27216
?
mi
from
Burlington, NC
Click here to add this to my saved trials
Burlington, Vermont 05405
?
mi
from
Burlington, VT
Click here to add this to my saved trials
Burlington, Wisconsin 53105
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
?
mi
from
Cameron Park, CA
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
2600 Sixth St. SW
Canton, Ohio 44710
330.363.4908
Aultman Health Foundation The Aultman Foundation will raise and administer funds in order to support...
?
mi
from
Canton, OH
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
6501 E 2nd St
Casper, Wyoming 82609
(307) 235-5433
Rocky Mountain Oncology Rocky Mountain Oncology Center is a spacious, comfortable, state-of-the-art 19,000 square foot...
?
mi
from
Casper, WY
Click here to add this to my saved trials
20126 Stanton Ave
Castro Valley, California 94546
(510) 581-0556
East Bay Radiation Oncology Center East Bay Radiation Oncology Center offers superior medical and technical...
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Castro Valley, California 94546
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Cedar Rapids, Iowa 52403
?
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
?
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centerville, Ohio 45459
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centralia, Illinois 62801
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Centralia, Washington 98531
?
mi
from
Centralia, WA
Click here to add this to my saved trials
Chadds Ford, Pennsylvania 19317
?
mi
from
Chadds Ford, PA
Click here to add this to my saved trials